Pharmacokinetics of First-Line Anti-Tubercular Drugs

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Indian Journal of Pediatrics

• Publication date

  2019-03-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12098-019-02911-wPMID 30915644
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India

  2019cited by this paper
• High-dose rifampicin, moxifl oxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

  2019cited by this paper
• Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status

  2018cited by this paper
• The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis

  2018cited by this paper
• Evaluation of the Adequacy of WHO Revised Dosages of the First-Line Antituberculosis Drugs in Children with Tuberculosis Using Population Pharmacokinetic Modeling and Simulations

  2018cited by this paper
• ERS Special Article. Efficacy and Safety of High‐Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial

  2018cited by this paper
• A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs

  2018cited by this paper
• Intra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazid

  2018cited by this paper
• Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!

  2018cited by this paper
• Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV‐Coinfected Children in India: Recommendations for Dose Modifications

  2018cited by this paper
• Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children

  2017cited by this paper
• Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs

  2017cited by this paper
• Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis

  2017cited by this paper
• Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis

  2017cited by this paper
• High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

  2017cited by this paper
• SLCO1B1 gene polymorphisms do not influence plasma rifampicin concentrations in a South Indian population.

  2016cited by this paper
• Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests

  2016cited by this paper
• Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis

  2016cited by this paper
• Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status

  2016cited by this paper
• Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol

  2015cited by this paper
• Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children

  2015cited by this paper
• Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis

  2014cited by this paper
• Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.

  2014cited by this paper
• Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.

  2013cited by this paper
• Pharmacokinetics of isoniazid in Ethiopian children with tuberculosis in relation to the N-acetyltransferase 2 (NAT2 ) genotype

  2013cited by this paper
• Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model.

  2013cited by this paper
• Blood levels of pyrazinamide in children at doses administered under the revised national tuberculosis control program

  2012cited by this paper
• Therapeutic Drug Monitoring in the Treatment of Tuberculosis

  2012cited by this paper
• Pharmacokinetics of anti‐tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations

  2012cited by this paper
• Isoniazid Pharmacokinetics, Pharmacodynamics, and Dosing in South African Infants

  2012cited by this paper
• ECHOVIRUS 18 MENINGITIS IN SOUTHERN TAIWAN

  2011cited by this paper
• Pharmacokinetics of Isoniazid, Rifampin, and Pyrazinamide in Children Younger than Two Years of Age with Tuberculosis: Evidence for Implementation of Revised World Health Organization Recommendations

  2011cited by this paper
• In Silico Children and the Glass Mouse Model: Clinical Trial Simulations To Identify and Individualize Optimal Isoniazid Doses in Children with Tuberculosis

  2010cited by this paper
• Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis

  2010cited by this paper
• A systematic review of pharmacokinetics studies in children with protein-energy malnutrition

  2010cited by this paper
• Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin Concentrations

  2010cited by this paper
• Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.

  2009cited by this paper
• Pathophysiological changes that affect drug disposition in protein-energy malnourished children

  2009cited by this paper
• Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis

  2009cited by this paper
• Rifampicin serum levels in childhood tuberculosis.

  2009cited by this paper
• Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses.

  2008cited by this paper
• Pyrazinamide serum levels in childhood tuberculosis.

  2008cited by this paper
• Pharmacokinetics of pyrazinamide in children with primary progressive disease of lungs.

  2008cited by this paper
• Ethambutol in paediatric tuberculosis: aspects of ethambutol serum concentration, efficacy and toxicity in children.

  2007cited by this paper
• Guidance for National Tuberculosis Programmes on the management of tuberculosis in children - an update.

  2007cited by this paper
• Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 1: introduction and diagnosis of tuberculosis in children.

  2006cited by this paper
• Low Levels of Pyrazinamide and Ethambutol in Children with Tuberculosis and Impact of Age, Nutritional Status, and Human Immunodeficiency Virus Infection

  2006cited by this paper
• Isoniazid pharmacokinetics in children treated for respiratory tuberculosis

  2005cited by this paper
• Applicability of the principles of developmental pharmacology to the study of environmental toxicants.

  2004cited by this paper
• Pharmacokinetics of ethambutol in children and adults with tuberculosis.

  2004cited by this paper
• Population Pharmacokinetic Modeling of Pyrazinamide in Children and Adults with Tuberculosis

  2002cited by this paper
• Isoniazid pharmacokinetics in children according to acetylator phenotype

  2001cited by this paper
• Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis.

  1999cited by this paper
• Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.

  1999cited by this paper
• Isoniazid acetylation metabolic ratio during maturation in children

  1997cited by this paper
• Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis.

  1997cited by this paper
• Rifampin and rifabutin and their metabolism by human liver esterases.

  1997cited by this paper
• Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.

  1996cited by this paper
• Isoniazid and acetylisoniazid kinetics in serum and urine in pulmonary primary complex with intermittent regimen.

  1994cited by this paper
• Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia

  1993cited by this paper
• Serum concentrations of rifampicin and isoniazid in tuberculosis.

  1993cited by this paper
• Cerebrospinal fluid isoniazid concentrations in children with tuberculous meningitis: the influence of dosage and acetylation status.

  1992cited by this paper
• Drug therapy in malnutrition.

  1992cited by this paper
• INH and Streptomycin in Ethiopian Children with Tuberculosis and Different Nutritional Status

  1988cited by this paper
• Goodman and Gilman's the Pharmacological Basis of Therapeutics

  1986cited by this paper
• Drug disposition in children with protein energy malnutrition.

  1983cited by this paper
• Pharmacokinetics of rifampin in infants and children: relevance to prophylaxis against Haemophilus influenzae type b disease.

  1980cited by this paper
• CONTROL OF STREPTOMYCIN AND ISONIAZID IN MALNOURISHED CHILDREN TREATED FOR TUBERCULOSIS

  1977cited by this paper
• Ethambutol and rifampicin serum levels in children: Second report on the combined administration of ethambutol and rifampicin

  1973cited by this paper
• Concentrations of active isoniazid in serum and cerebrospinal fluid of patients with tuberculosis treated with isoniazid.

  1958cited by this paper
• Systemic treatment of primary tuberculosis.

  1956cited by this paper
• Systematic treatment of primary tuberculosis.

  1956cited by this paper
• Annals of Clinical Microbiology and Antimicrobials Roles of Rifampicin in Drug-drug Interactions: Underlying Molecular Mechanisms Involving the Nuclear Pregnane X Receptor

  year unknowncited by this paper

• Optimizing Paediatric Tuberculosis Treatment: Efficacy and Safety of Immediate-Release Anti-Tubercular Formulations

  2024cites this paper
• Hepatoprotective Effect of the Ursolic Acid-Oleanolic Acid Mixture Administered Intragastrically in Mice with Liver Damage Induced by Anti-TB Drugs

  2023cites this paper
• Pharmacokinetic assessment of rifampicin and des-acetyl rifampicin in carbon tetrachloride induced liver injury model in Wistar rats

  2023cites this paper
• Mechanisms and detection methods of Mycobacterium tuberculosis rifampicin resistance: The phenomenon of drug resistance is complex.

  2021cites this paper
• Therapeutic drug monitoring of intravenous anti-tuberculous therapy: management of an 8-month-old child with tuberculous meningitis

  2021influential citation
• Лекарственная совместимость в лечении хронических инфекционных болезней

  2021cites this paper
• LipF increases rifampicin and streptomycin sensitivity in a Mycobacterium tuberculosis surrogate

  2020cites this paper
• Advances in Tuberculosis: Diagnostics

  2019cites this paper
• Vibrational spectra of pyrazinamide and isoniazid studied by terahertz spectroscopy and density functional theory.

  2019cites this paper
• Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!

  2018cites this paper